...FDA granted Orphan Drug designation for Accentia's Revimmune cyclophosphamide to prevent graft-versus-host disease (GvHD) following bone...
...in early 2012. Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, Dec. 6, 2010). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...

...FDA granted Orphan Drug designation for Accentia's Revimmune cyclophosphamide to treat systemic sclerosis and autoimmune hemolytic...
...Dec. 6, 2010). Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, March 5, 2007). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...

...autoimmune diseases including multiple sclerosis (MS) and systemic lupus erythematosus (SLE) showed that 50 mg/kg/day Revimmune...
...Dec. 6, 2010). Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune...
...BioCentury, March 5, 2007). Accentia Biopharmaceuticals Inc. (OTCQB:ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...

...indications. Accentia will use the supply to manufacture its Revimmune cyclophosphamide to treat autoimmine diseases. Revimmune...
...cyclophosphamide as part of Accentia's clinical and regulatory development of Revimmune for undisclosed autoimmune indications. Revimmune...
...were not disclosed. Accentia has exclusive, worldwide rights to Revimmune to treat autoimmune indications from Revimmune LLC...

...bankruptcy after filing in Nov. 2008. Under the plan, shareholders will retain their shares. Accentia's Revimmune...
...ultra-high intensity, short course of an IV formulation of cyclophosphamide to treat autoimmune indications from Revimmune LLC...

...this summer after which it will announce plans to start Phase III testing for its Revimmune...
...ultra-high intensity, short course of an IV formulation of cyclophosphamide to treat autoimmune indications from Revimmune LLC...

...Biovest received exclusive, worldwide rights to Revimmune's Revimmune cyclophosphamide to treat and prevent transplant rejection. Revimmune...
...closed at $0.50 on Jan. 18, the last trading day before the deal was announced. Revimmune...
...has exclusive, worldwide rights to Revimmune to treat autoimmune indications (see BioCentury, March 5, 2007). Revimmune...

...ABPI received an SPA from FDA for a 1-year Phase III trial of Revimmune cyclophosphamide in...
...see BioCentury, March 5). Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...

...Phase III trial in 270 patients. The company licensed exclusive rights to the product from Revimmune...
...see BioCentury, March 5). Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC , Tampa, Fla. Product: Revimmune...

...Revimmune cyclophosphamide to treat autoimmune indications. ABPI hopes to start a Phase III study of Revimmune...
...is marketed as a generic chemotherapeutic to treat various cancers. Upon approval of the product, Revimmune...
...deal was announced. Revimmune also is eligible for royalties. Accentia Biopharmaceuticals Inc. (ABPI), Tampa, Fla. Revimmune LLC...